We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.16 | 0.58% | 27.86 | 27.905 | 27.52 | 27.86 | 60,567,753 | 00:59:06 |
From May 2019 to May 2024
By Colin Kellaher
Merck & Co. (MRK) on Monday said the U.S. Food and Drug Administration approved its cancer drug Keytruda in combination with Pfizer Inc.'s (PFE) Inlyta for the first-line treatment of patients with advanced renal cell carcinoma, the most common type of kidney cancer.
The Kenilworth, N.J., drug maker said the approval is based on findings from a phase 3 study that showed significant improvements in overall survival, progression-free survival and objective response rate for the combination compared to sunitinib, a chemotherapy drug marketed by Pfizer as Sutent.
Merck said the approval marks the first indication in advanced renal cell carcinoma for Keytruda, a cancer drug that harnesses a patient's immune systems to fight tumors.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 22, 2019 07:16 ET (11:16 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
